TW202332432A - Egfr抑制劑的固態形式 - Google Patents

Egfr抑制劑的固態形式 Download PDF

Info

Publication number
TW202332432A
TW202332432A TW111147070A TW111147070A TW202332432A TW 202332432 A TW202332432 A TW 202332432A TW 111147070 A TW111147070 A TW 111147070A TW 111147070 A TW111147070 A TW 111147070A TW 202332432 A TW202332432 A TW 202332432A
Authority
TW
Taiwan
Prior art keywords
solid form
exhibits
ray powder
powder diffraction
group
Prior art date
Application number
TW111147070A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬 Ｗ 卡多爾
托菲克 卡諾尼
安德魯 菲米絲特
潔雅錢德拉 Ｐ 雷迪
約翰 泰納斯
夏巴漢 恰佩德
皮爾坦蘇 潘迪
傑森 考克斯
羅伯特 肯尼亞
Original Assignee
美商奇奈特生物製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商奇奈特生物製藥公司 filed Critical 美商奇奈特生物製藥公司
Publication of TW202332432A publication Critical patent/TW202332432A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
TW111147070A 2021-12-08 2022-12-07 Egfr抑制劑的固態形式 TW202332432A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163287212P 2021-12-08 2021-12-08
US63/287,212 2021-12-08

Publications (1)

Publication Number Publication Date
TW202332432A true TW202332432A (zh) 2023-08-16

Family

ID=86731361

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111147070A TW202332432A (zh) 2021-12-08 2022-12-07 Egfr抑制劑的固態形式

Country Status (12)

Country Link
US (1) US20250059170A1 (https=)
EP (1) EP4444302A4 (https=)
JP (1) JP2024542840A (https=)
KR (1) KR20240119095A (https=)
CN (1) CN118804748A (https=)
AU (1) AU2022407440A1 (https=)
CA (1) CA3239792A1 (https=)
CL (1) CL2024001679A1 (https=)
IL (1) IL313359A (https=)
MX (1) MX2024006933A (https=)
TW (1) TW202332432A (https=)
WO (1) WO2023107980A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
AU2022407439A1 (en) * 2021-12-08 2024-06-27 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10124003B2 (en) * 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
EP3969442A4 (en) * 2019-05-17 2023-08-02 Kinnate Biopharma Inc. FIBROBLAST GROWTH FACTOR RECEPTOR KINASE INHIBITORS
US11345681B1 (en) * 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases

Also Published As

Publication number Publication date
IL313359A (en) 2024-08-01
KR20240119095A (ko) 2024-08-06
EP4444302A1 (en) 2024-10-16
WO2023107980A1 (en) 2023-06-15
AU2022407440A1 (en) 2024-06-20
CA3239792A1 (en) 2023-06-15
CL2024001679A1 (es) 2024-11-29
US20250059170A1 (en) 2025-02-20
CN118804748A (zh) 2024-10-18
EP4444302A4 (en) 2025-09-03
MX2024006933A (es) 2024-08-26
JP2024542840A (ja) 2024-11-15

Similar Documents

Publication Publication Date Title
US11123338B2 (en) C-met modulator pharmaceutical compositions
US20090247532A1 (en) Crystalline polymorph of sitagliptin phosphate and its preparation
CN117164581A (zh) 一种kras抑制剂或其盐的多晶型物及其制剂制备
KR20210013554A (ko) Tlr7/tlr8 억제제의 결정질 형태
JP7825636B2 (ja) （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
EP3666776A1 (en) Hydrate of a gonadotropin-releasing hormone receptor antagonist
TW202332432A (zh) Egfr抑制劑的固態形式
JP2025131661A (ja) ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
TW201040161A (en) Crystalline polymorphic form 631
WO2020244612A1 (zh) Cdk9抑制剂的多晶型物及其制法和用途
US9453011B2 (en) Crystal form of dabrafenib mesylate and preparation method thereof
KR20200140821A (ko) 아베마시클립의 고체-상태 형태, 그의 용도 및 제조
JP2013543495A (ja) 強力なｈｃｖインヒビターの固体形体
TWI922665B (zh) (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式
TW201125861A (en) CDC7 inhibitor salts
HK40107041A (zh) 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2，2，2-三氟乙基)吡咯烷-1-甲酰胺及其盐
HK40115548A (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
HK1185553B (en) C-met modulator pharmaceutical compositions